Access Digital Health
CountriesInterventionsToolsAbout
Log in
← Interventions

Oral prednisolone for COPD exacerbation

Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$338–370
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
1
Tier A · 0 studies
Source agreement
comparable
within 2.5×
Scope to country:All countries
Loading effectiveness evidence…
Cost-effectiveness

Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.

Modeled benchmarks ($/DALY)Tier A · standardized benchmark
South-East Asia$338.00View source →
Eastern sub-Saharan Africa$370.00View source →

WHO-CHOICE estimates are modeled at 50% population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →

$/DALY sources within 2.5x - treat as comparable, not ranked.

Modeled regional estimates — not realized delivery costs.

Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Delivery readiness is not currently shown. The country health-system view — workforce density, financing mix, service coverage — is being rebuilt as part of the scenario layer. The underlying indicators remain in the country pages.
The figures above are published benchmarks. To build an investment case for your own context — local unit costs, target population, coverage assumptions — model it directly. Select a country first to carry its context into the model.
Choose a country to model →
Looking for supply/market data for Oral prednisolone for COPD exacerbation? Select a country above, then open its intelligence page.